Understanding the mechanisms of faecal microbiota transplantation

Nature Reviews Gastroenterology and Hepatology

Volumn 13, Issue 9, 2016, Pages 508-516

  Khoruts, Alexander ^a   Sadowsky, Michael J ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOCIN; COLESTIPOL; COLESTYRAMINE; INTERLEUKIN 1; INTERLEUKIN 22; INTERLEUKIN 23; LANTIBIOTIC; MEVINOLIN; OBETICHOLIC ACID; URSODEOXYCHOLIC ACID; VANCOMYCIN; BILE ACID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL TRANSLOCATION; BACTEROIDETES; BILE ACID METABOLISM; CLOSTRIDIUM DIFFICILE INFECTION; COMMENSAL; DYSBIOSIS; ENGRAFTMENT; EXTRACELLULAR TRAP; FECAL MICROBIOTA TRANSPLANTATION; FIRMICUTES; HUMAN; ILEITIS; INTESTINE FLORA; MICROBIAL DIVERSITY; MUCOSAL IMMUNITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; REVIEW; SPORE GERMINATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; CLOSTRIDIUM INFECTIONS; FORECASTING; METABOLISM; PHYSIOLOGY;

BILE ACIDS AND SALTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FORECASTING; GASTROINTESTINAL MICROBIOME; HUMANS;

EID: 84975292883     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2016.98     Document Type: Review

References (107)

1. Fischbach, M. A. & Walsh, C. T. Antibiotics for emerging pathogens. Science 325, 1089-1093 (2009).
2. Laxminarayan, R. et al. Antibiotic resistance-the need for global solutions. Lancet Infect. Dis. 13, 1057-1098 (2013).
3. Kelly, C. P. & LaMont, J. T. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359, 1932-1940 (2008).
4. Lessa, F. C. et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825-834 (2015).
5. Borody, T. J. & Khoruts, A. Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 9, 88-96 (2012).
6. McFarland, L. V., Elmer, G. W. & Surawicz, C. M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 97, 1769-1775 (2002).
7. Khoruts, A., Dicksved, J., Jansson, J. K. & Sadowsky, M. J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J. Clin. Gastroenterol. 44, 354-360 (2010).
8. Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A. & Sadowsky, M. J. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4, 125-135 (2013).
9. van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415 (2013).
10. Shankar, V. et al. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome 2, 13 (2014).
11. Seekatz, A. M. et al. Recovery of the gut microbiome following fecal microbiota transplantation. mBio 5, e00893-e00814 (2014).
12. Weingarden, A. et al. Dynamic changes in short-and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome 3, 10 (2015).
13. Weingarden, A. R. et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G310-G319 (2014).
14. Drekonja, D. et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann. Intern. Med. 162, 630-638 (2015).
15. Weingarden, A. R., Hamilton, M. J., Sadowsky, M. J. & Khoruts, A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J. Clin. Gastroenterol. 47, 735-737 (2013).
16. Fischer, M. et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment. Pharmacol. Ther. 42, 470-476 (2015).
17. Markelov, A., Livert, D. & Kohli, H. Predictors of fatal outcome after colectomy for fulminant Clostridium difficile Colitis: a 10-year experience. dr. markelov@ gmail. com. Am. Surg. 77, 977-980 (2011).
18. Lamontagne, F. et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann. Surg. 245, 267-272 (2007).
19. Hamilton, M. J., Weingarden, A. R., Sadowsky, M. J. & Khoruts, A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107, 761-767 (2012).
20. Youngster, I. et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312, 1772-1778 (2014).
21. Chang, J. Y. et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197, 435-438 (2008).
22. Broecker, F. et al. Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation. Cold Spring Harb. Mol. Case Stud. 2, a000448 (2016).
23. Kostic, A. D., Xavier, R. J. & Gevers, D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146, 1489-1499 (2014).
24. Angelberger, S. et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am. J. Gastroenterol. 108, 1620-1630 (2013).
25. Kump, P. K. et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm. Bowel Dis. 19, 2155-2165 (2013).
26. Rossen, N. G. et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149, 110-1184 (2015).
27. Moayyedi, P. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102-109. e6 (2015).
28. Kolho, K. L. et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am. J. Gastroenterol. 110, 921-930 (2015).
29. Busquets, D. et al. Anti-tumour necrosis factor treatment with adalimumab induces changes in the microbiota of Crohn's disease. J. Crohns Colitis 9, 899-906 (2015).
30. Damman, C. J. et al. Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis. PLoS ONE 10, e0133925 (2015).
31. Backhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A. & Gordon, J. I. Host-bacterial mutualism in the human intestine. Science 307, 1915-1920 (2005).
32. Fuentes, S. et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J. 8, 1621-1633 (2014).
33. Chehoud, C. et al. Transfer of viral communities between human individuals during fecal microbiota transplantation. mBio 7, e00322-e00316 (2016).
34. Miller, M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 15, 281-284 (2009).
35. Petrof, E. O. et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 1, 3 (2013).
36. O'Connor, J. R., Johnson, S. & Gerding, D. N. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136, 1913-1924 (2009).
37. Lessa, F. C., Gould, C. V. & McDonald, L. C. Current status of Clostridium difficile infection epidemiology. Clin. Infect. Dis. 55, S65-S70 (2012).
38. Sender, R., Fuchs, S. & Milo, R. Are we really vastly outnumbered Revisiting the ratio of bacterial to host cells in humans. Cell 164, 337-340 (2016).
39. Ng, K. M. et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502, 96-99 (2013).
40. Wilson, K. H. & Perini, F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect. Immun. 56, 2610-2614 (1988).
41. Kopke, M., Straub, M. & Durre, P. Clostridium difficile is an autotrophic bacterial pathogen. PLoS ONE 8, e62157 (2013).
42. Gerding, D. N. et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313, 1719-1727 (2015).
43. Lawley, T. D. et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8, e1002995 (2012).
44. Lenski, R. E. & Riley, M. A. Chemical warfare from an ecological perspective. Proc. Natl Acad. Sci. USA 99, 556-558 (2002).
45. Rea, M. C. et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc. Natl Acad. Sci. USA 107, 9352-9357 (2010).
46. Breukink, E. & de Kruijff, B. The lantibiotic nisin, a special case or not Biochim. Biophys. Acta 1462, 223-234 (1999).
47. Le Lay, C., Dridi, L., Bergeron, M. G., Ouellette, M. & Fliss, I. Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. J. Med. Microbiol. 65, 169-175 (2016).
48. Lakshminarayanan, B. et al. Prevalence and characterization of Clostridium perfringens from the faecal microbiota of elderly Irish subjects. J. Med. Microbiol. 62, 457-466 (2013).
49. Ross, R. P., Morgan, S. & Hill, C. Preservation and fermentation: past, present and future. Int. J. Food Microbiol. 79, 3-16 (2002).
50. Rea, M. C. et al. Antimicrobial activity of lacticin 3, 147 against clinical Clostridium difficile strains. J. Med. Microbiol. 56, 940-946 (2007).
51. McAuliffe, O. et al. Lacticin 3147, a broad-spectrum bacteriocin which selectively dissipates the membrane potential. Appl. Environ. Microbiol. 64, 439-445 (1998).
52. Bakken, J. S. Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. Clin. Infect. Dis. 59, 858-861 (2014).
53. Heinlen, L. & Ballard, J. D. Clostridium difficile infection. Am. J. Med. Sci. 340, 247-252 (2010).
54. Wilson, K. H. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J. Clin. Microbiol. 18, 1017-1019 (1983).
55. Bhattacharjee, D. et al. Reexamining the germination phenotypes of several Clostridium difficile strains suggests another role for the CspC germinant receptor. J. Bacteriol. 198, 777-786 (2015).
56. Browne, H. P. et al. Culturing of 'unculturable' human microbiota reveals novel taxa and extensive sporulation. Nature 533, 543-546 (2016).
57. Francis, M. B., Allen, C. A., Shrestha, R. & Sorg, J. A. Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog. 9, e1003356 (2013).
58. Burns, D. A., Heap, J. T. & Minton, N. P. SleC is essential for germination of Clostridium difficile spores in nutrient-rich medium supplemented with the bile salt taurocholate. J. Bacteriol. 192, 657-664 (2010).
59. Sorg, J. A. & Sonenshein, A. L. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192, 4983-4990 (2010).
60. Hofmann, A. F. & Hagey, L. R. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65, 2461-2483 (2008).
61. Weingarden, A. R. et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLoS ONE 11, e0147210 (2016).
62. Mekhjian, H. S., Phillips, S. F. & Hofmann, A. F. Colonic absorption of unconjugated bile acids: perfusion studies in man. Dig. Dis. Sci. 24, 545-550 (1979).
63. Bennion, L. J. et al. Sex differences in the size of bile acid pools. Metabolism 27, 961-969 (1978).
64. Lee, C. H. et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1425-1428 (2014).
65. Agrawal, M. et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J. Clin. Gastroenterol. 146, 542-S-43 (2015).
66. Khoruts, A. et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin. Gastroenterol. Hepatol. http://dx. doi. org/10. 1016/j. cgh. 2016. 02. 018 (2016).
67. Hammons, J. L., Jordan, W. E., Stewart, R. L., Taulbee, J. D. & Berg, R. W. Age and diet effects on fecal bile acids in infants. J. Pediatr. Gastroenterol. Nutr. 7, 30-38 (1988).
68. Jangi, S. & Lamont, J. T. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J. Pediatr. Gastroenterol. Nutr. 51, 2-7 (2010).
69. Hafiz, S. & Oakley, C. L. Clostridium difficile: isolation and characteristics. J. Med. Microbiol. 9, 129-136 (1976).
70. Pothoulakis, C. & Lamont, J. T. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G178-G183 (2001).
71. Hill, C. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506-514 (2014).
72. Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205-208 (2015).
73. Gerding, D. N., Muto, C. A. & Owens, R. C. Jr Treatment of Clostridium difficile infection. Clin. Infect. Dis. 46, S32-S42 (2008).
74. Mogg, G. A. et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br. J. Surg. 69, 137-139 (1982).
75. Cohen, S. H. et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455 (2010).
76. Bertolotti, M. et al. Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7-hydroxylation rates in vivo. Hepatology 14, 830-837 (1991).
77. Reihner, E. et al. Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients. J. Lipid Res. 31, 2219-2226 (1990).
78. Bertolotti, M. et al. Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology 38, 939-946 (2003).
79. Walters, J. R. et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment. Pharmacol. Ther. 41, 54-64 (2015).
80. Zhang, J. H. et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G940-G948 (2013).
81. Weingarden, A. R. et al. Ursodeoxycholic acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J. Clin. Gastroenterol. http://dx. doi. org/10. 1097/MCG. 0000000000000427 (2015).
82. Rodrigues, C. M., Kren, B. T., Steer, C. J. & Setchell, K. D. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 109, 1835-1844 (1995).
83. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121-141 (2014).
84. Vaishnava, S. et al. The antibacterial lectin RegIII promotes the spatial segregation of microbiota and host in the intestine. Science 334, 255-258 (2011).
85. Voth, D. E. & Ballard, J. D. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18, 247-263 (2005).
86. El Feghaly, R. E. et al. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin. Infect. Dis. 56, 1713-1721 (2013).
87. Xu, H. et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513, 237-241 (2014).
88. Ng, J. et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 139, 542-552. e3 (2010).
89. Hasegawa, M. et al. Protective role of commensals against Clostridium difficile infection via an IL-1-mediated positive-feedback loop. J. Immunol. 189, 3085-3091 (2012).
90. Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535 (2004).
91. Papayannopoulos, V. & Zychlinsky, A. NETs: a new strategy for using old weapons. Trends Immunol. 30, 513-521 (2009).
92. Buonomo, E. L. et al. Role of interleukin 23 signaling in Clostridium difficile colitis. J. Infect. Dis. 208, 917-920 (2013).
93. Cowardin, C. A. et al. Inflammasome activation contributes to interleukin-23 production in response to Clostridium difficile. mBio 6, e02386-e02314 (2015).
94. Dudakov, J. A., Hanash, A. M. & van den Brink, M. R. Interleukin-22: immunobiology and pathology. Annu. Rev. Immunol. 33, 747-785 (2015).
95. Hasegawa, M. et al. Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity 41, 620-632 (2014).
96. Aroniadis, O. C. & Brandt, L. J. Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroenterol. 29, 79-84 (2013).
97. Smits, L. P., Bouter, K. E., de Vos, W. M., Borody, T. J. & Nieuwdorp, M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 145, 946-953 (2013).
98. Backhed, F. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 852 (2015).
99. Olszak, T. et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336, 489-493 (2012).
100. Khoruts, A. First microbial encounters. Nat. Med. 22, 231-232 (2016).
101. Modi, S. R., Collins, J. J. & Relman, D. A. Antibiotics and the gut microbiota. J. Clin. Invest. 124, 4212-4218 (2014).
102. Taur, Y. et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 55, 905-914 (2012).
103. US National Library of Science. ClinicalTrials. gov https://clinicaltrials. gov/ct2/show/NCT02269150 (2016).
104. Stripling, J. et al. Loss of vancomycin-resistant enterococcus fecal dominance in an organ transplant patient with Clostridium difficile colitis after fecal microbiota transplant. Open Forum Infect Dis 2, ofv078 (2015).
105. Dethlefsen, L., McFall-Ngai, M. & Relman, D. A. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449, 811-818 (2007).
106. Smith, M. B., Kelly, C. & Alm, E. J. Policy: how to regulate faecal transplants. Nature 506, 290-291 (2014).
107. Bakken, J. S. et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 9, 1044-1049 (2011).